Core Viewpoint - CAR-T cell therapy shows strong efficacy in hematological cancers and autoimmune diseases, but struggles with solid tumors due to antigen heterogeneity and immunosuppressive tumor microenvironment (TME) [2] Group 1: Research Findings - The study published on December 11, 2025, in Cancer Cell demonstrates that IL-36γ armored CAR-T cells can reprogram neutrophils to induce endogenous antitumor immunity, effectively clearing solid tumors and overcoming key obstacles faced by adoptive cell therapy for solid tumors [2][5] - IL-36γ is a pro-inflammatory cytokine that enhances CAR-T cell persistence and positively modulates the TME, leading to an endogenous antitumor immune response [5] - The research indicates that IL-36γ armored CAR-T cells can eradicate primary solid tumors without prior lymphocyte depletion and can activate cancer immune cycles by reprogramming neutrophils [6][8] Group 2: Mechanism of Action - The reprogrammed neutrophils exhibit tumor-killing capabilities and antigen-presenting functions, which are crucial for recognizing tumor antigens beyond the CAR-targeted antigens [5][6] - The combination of CAR-T cells and neutrophils is identified as a key step in establishing cancer immune cycles, introducing a broadly applicable method to address the challenges of solid tumor therapies [8]